{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03368274",
      "orgStudyIdInfo": {
        "id": "IgG4-RD Iguratimod"
      },
      "organization": {
        "fullName": "Peking Union Medical College Hospital",
        "class": "OTHER"
      },
      "briefTitle": "To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom",
      "officialTitle": "To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom"
    },
    "statusModule": {
      "statusVerifiedDate": "2018-04",
      "overallStatus": "UNKNOWN",
      "lastKnownStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2017-09-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2018-06-01",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2018-06-01",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2017-09-20",
      "studyFirstSubmitQcDate": "2017-12-05",
      "studyFirstPostDateStruct": {
        "date": "2017-12-11",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2018-04-10",
      "lastUpdatePostDateStruct": {
        "date": "2018-04-11",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR_INVESTIGATOR",
        "investigatorFullName": "Wen Zhang",
        "investigatorTitle": "professor",
        "investigatorAffiliation": "Peking Union Medical College Hospital"
      },
      "leadSponsor": {
        "name": "Wen Zhang",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "30 untreated IgG4 related disease (IgG4-RD) patients with mild symptom are enrolled in this study, and will be treated with one dose of diprospan,then take Iguratimod 25mg, Bid orally. Patient's peripheral blood will be collected at baseline, 12 weeks and 24 weeks of follow up. The clinical efficacy will be evaluated by the IgG4-RD responder index, serum immunoglobulin, IgG4 and IgE, cytokines, and peripheral blood T cell and B cell sub-populations will be measured at baseline and follow up.",
      "detailedDescription": "Glucocorticoid is the recognized first-line medication for IgG4-RD, but it has many side effects. In order to avoid long time glucocorticoids intake, patients with mild disease will be treated with Iguratimod combined with one dose of diprospan. 30 untreated IgG4-RD patients with mild symptom will be enrolled in this study, and be treated with one dose of diprospan,then take Iguratimod 25mg, Bid orally. 5 ml of patients' peripheral blood will be collected at baseline, 12 weeks and 24 weeks of follow up. At baseline and each follow-up, the clinical efficacy of treatment will be evaluated by IgG4-RD responder index, serum immunoglobulin, IgG4, immunoglobulin E (IgE), serum cytokines, such as interleukin 1, 6, and tumor necrosis factor, will be measured by ELISA, peripheral blood T cell sub-populations, B cell sub-populations and plasma cells will be measured by flow-cytometry."
    },
    "conditionsModule": {
      "conditions": [
        "IgG4-related Disease"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "interventionModelDescription": "To compare IgG4-RD responder index, serum parameters and blood lymphocytes subpopulations at baseline and after treatment of 12 weeks and 24 weeks",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 30,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Signal arm study",
          "type": "EXPERIMENTAL",
          "description": "Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.",
          "interventionNames": [
            "Drug: T 614"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "T 614",
          "description": "Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.",
          "armGroupLabels": [
            "Signal arm study"
          ],
          "otherNames": [
            "diprospan"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "The change of IgG4-RD responder index before treatment and after treatment",
          "description": "Evaluate patients baseline and follow-up IgG4-RD responder index(disease activity)",
          "timeFrame": "24 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Changes of serum immunoglobulins subclass IgG4 levels",
          "description": "The IgG4 levels are tested routinely.",
          "timeFrame": "24 weeks"
        },
        {
          "measure": "Patients serum cytokines",
          "description": "patients serum of cytokines detection by ELISA.",
          "timeFrame": "24 weeks"
        },
        {
          "measure": "Peripheral blood lymphocytes sub-populations",
          "description": "Peripheral blood T,B sub-populations by flowcytometry",
          "timeFrame": "24 weeks"
        },
        {
          "measure": "Side effects",
          "description": "Side effects, including laboratory tests will be recorded and tested.",
          "timeFrame": "24 weeks"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Mikulicz disease, with/without nasosinusitis or lymph node swelling.\n* Without internal organs affected,\n* With slow disease progression.\n\nExclusion Criteria:\n\n* Vital organs related:including autoimmune pancreatitis,retroperitoneal fibrosis, sclerosing cholangitis, lung related, kidney affected, IgG4 related castleman's disease and hypophysitisï¼Œ\n* Combined with other connective disease,\n* With tumors,\n* Pregnancy or to be pregnant,\n* Active infection, including hepatitis B virus, hepatitis C virus, and tuberculosis.\n* Leucocytopenia, impairment of liver and kidney function,\n* Allergy of Iguratimod, or cannot tolerate Iguratimod.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "70 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Wen Zhang",
          "role": "CONTACT",
          "phone": "86-10-69158795",
          "email": "zhangwen91@sina.com"
        }
      ],
      "overallOfficials": [
        {
          "name": "Wen Zhang",
          "affiliation": "Peking Union Medical College Hospital",
          "role": "STUDY_CHAIR"
        }
      ],
      "locations": [
        {
          "facility": "Peking Union Medical College Hospital",
          "status": "RECRUITING",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100032",
          "country": "China",
          "contacts": [
            {
              "name": "Panpan Zhang",
              "role": "CONTACT",
              "phone": "+8618800159311",
              "email": "panpanzhang2016@163.com"
            },
            {
              "name": "Wen Zhang",
              "role": "CONTACT",
              "email": "zhangwen91@sina.com"
            }
          ],
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D000077733",
          "term": "Immunoglobulin G4-Related Disease"
        }
      ],
      "ancestors": [
        {
          "id": "D001327",
          "term": "Autoimmune Diseases"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C077313",
          "term": "T 614"
        },
        {
          "id": "C032812",
          "term": "betamethasone dipropionate, betamethasone sodium phosphate drug combination"
        }
      ]
    }
  },
  "hasResults": false
}